Augmentation strategies in STAR*D: A review

Primary Psychiatry

Volumn 14, Issue 1, 2007, Pages 46-50

  Denko, Timothey C ^a   Friedman, Edward S ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

COGNITIVE THERAPY; HUMAN; MAJOR DEPRESSION; REMISSION; REVIEW; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME;

EID: 33846382787     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006;163(9):1561-1568.
2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.
3. Stein MB, Cox BJ, Afifi TO, Belik SL, Sareen J. Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective. Psychol Med. 2006;36(5):587-596.
4. Friedman ES, Thase ME. Cognitive-behavioral therapy for depression and dysthymia. In: Stein DJ, Kupfer DJ, Schatzberg AF, eds. The American Psychiatric Publishing Textbook of Mood Disorders. Washington, DC: American Psychiatric Publishing; 2005:353-371.
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
6. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biol Psychiatry. 2006;59(6):493-501.
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
8. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31(9):1841-1853.
9. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457-494.
10. Fava M. Augmentation and combination strategies in treatment-resistant depression. Am J Psychiatry. 2001;62(suppl 18):4-11.
11. Aronson R, Hoffman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-848.
12. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and buproprion-SR: combining versus switching patients with treatment-resistant depression. J Clin Psychiatry. 2004;65(3):337-340.
13. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
14. Wisniewski SR, Rush AJ, Balasubramani GK, et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. In press.
15. STAR*D. Assessment Forms. Available at: www.edc.pitt.edu/stard/ public/assessment_forms.html. Accessed December 7, 2006.
16. Thase ME. STAR*D Level 2 acute and longer-term outcomes with cognitive therapy. Poster presented at: 47th Annual Meeting of the New Clinical Drug Evaluation Unit; June 13, 2006; Boca Raton, FL.
17. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243- 1252.
18. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine XR after failure of SSRIs for depression. N Eng J Med. 2006;354(12):1231-1242.
19. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530.